Arthur Pharma

Zhejiang Arthur Pharmaceutical Co., Ltd. is a biopharmaceutical company established in March 2020, headquartered in Jiaxing, China, with an R&D center in Princeton, USA. The company focuses on the development, manufacturing, and commercialization of high-end generic and innovative drugs. The founder, Chairman, and CEO, Liu Hongbin, holds a Ph.D. in Biophysics and Biochemistry from Stanford University and has prior experience in senior roles at multinational pharmaceutical companies such as McKinsey, Novartis, and Pfizer.

Arthur Pharma's therapeutic areas of focus include anti-infective drugs, anti-tumor drugs, neuropsychiatric drugs, and treatments for chronic conditions like cardiovascular diseases, gastrointestinal disorders, and diabetes. The company's R&D capabilities allow for the development of various drug dosage forms, including tablets, capsules, injections, and semi-solids. Their product pipeline encompasses oral solids, as well as sterile and semi-solid formulations, with sterile products including lyophilization, drops, liquid self-emulsifying formulations, nanoparticle suspensions, and liposomes. The company operates with a core research team largely composed of graduates from prominent institutions like East China University of Science and Technology, China Pharmaceutical University, and Shenyang Pharmaceutical University.

The company's business model includes the sale of its pharmaceutical products and also provides Contract Research Organization (CRO), Contract Manufacturing Organization (CMO), and Contract Development and Manufacturing Organization (CDMO) services. This dual approach allows them to generate revenue from their own product lines as well as from providing services to other pharmaceutical entities. Arthur Pharma has established multiple manufacturing facilities in North America and Asia through CMO collaborations, and has partners across Asia, the United States, and Europe. Since its founding, the company has secured significant funding, including a Series A round in April 2022, a Series A1 in January 2023, and a Series B round in June 2024, with investors such as CMBC Capital, Addor Capital, and yidagroup.com.cn.

Keywords: generic drugs, innovative drugs, drug development, pharmaceutical manufacturing, biopharmaceutical, CRO services, CDMO services, CMO services, oncology, anti-infective, neuropsychiatry, cardiovascular diseases, diabetes treatment, oral solid dosage, sterile injectables, clinical research, pharmaceutical R&D, drug commercialization, global pharma, Jiaxing biopharma